A more holistic approach to the care and treatment of patients with psoriasis and psoriatic arthritis has been found beneficial to patients.
The role of mechanoinflammation in the pathogenesis of psoriatic disease and the presence of entheseal lesions as predictors of the onset of clinical joint disease gain support in a new study.
Real-world utilization of biologics for the treatment of psoriasis and psoriatic arthritis reveals interesting trends and surprising practices, finds an analysis.
Recently released guidelines from Japan outline the factors that may influence the choice of biologic agents for treatment in patients with psoriasis.
The off-label use of treatments is especially prevalent in dermatology as the need for effective therapies outpaces the approval process. Experts discuss the most commonly employed treatments, the ethical implications of off-label use, and the need for patient education.
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
Patients with hidradenitis suppurativa display increased risks for developing ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, a study finds.
Patients with psoriasis are more likely to continue treatment with biologics than with conventional therapies, for a number of possible reasons, a French study has noted.
Patients with psoriasis showed an increased risk for ESRD development although patients who received systemic anti-psoriasis agents did not, a nationwide cohort study reveals.
Researchers reported on the clinical response of a patient with psoriatic nail dystrophy and psoriatic arthritis who received treatment with tildrakizumab.
